gutflix
GI learning, personalised

Summary

NOVEL FIBROSIS BIOMARKERS IN SERUM AND PANCREATIC FLUID COLLECTIONS

Amer Hadi

UEG Week Copenhagen 2023 | Poster

Pancreas

October 16, 2023

A prospective study of 43 patients with pancreatic fluid collections found elevated serum fibrosis biomarkers compared to healthy controls and differential distribution of five collagen biomarkers between pancreatic fluid and serum, suggesting both local and systemic fibrotic activity.

KEY POINTS

- All five fibrosis biomarkers (PRO-C3, C3M, PRO-C11, PRO-C19, C4M) were significantly elevated in serum of patients with pancreatic fluid collections compared to healthy controls ($p<0.001$ for all).
- PRO-C3 levels were significantly higher in pancreatic fluid than serum (median 280.6 vs. 20.8 ng/mL, $p<0.001$), which the authors interpret as indicating localized fibrotic activity.
- C3M, PRO-C19, and C4M showed significantly higher serum levels compared to pancreatic fluid ($p=0.003$, $p<0.001$, $p<0.001$ respectively), interpreted by the authors as indicating increased systemic fibrosis.
- The study included 43 patients (26 with walled-off necrosis, 17 with pseudocysts) who underwent endoscopic ultrasound-guided drainage with simultaneous blood and pancreatic fluid sampling between August 2019 and January 2022.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/67dd6f0a-743c-11ee-9586-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.